A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8179 participants.
Also called NCT01492361
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 8,179 participants
- Sponsor
- Amarin Pharma Inc.
- Registry
-
NCT01492361
-
- Main results
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- Other papers using this trial's data
- Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
- Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT
- Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
- Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States
- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
- Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG
- Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT
- Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
- REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
- Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
- Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russia, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01492361. Randomized; triple masking; primary purpose prevention. Start 2011-11 (actual); primary completion 2018-05 (actual). Results posted on 2022-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
- Acronym
- REDUCE-IT
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- AMR101
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Statin therapy
- Lead sponsor
- Amarin Pharma Inc.
Record details
- Record id
cardio:ct-nct01492361- Content hash
1792aa68ff191347e713f75a035fd82c7deb354e80a4df3c0a53c1424f38254a